Viking Therapeutics Reports Q3 2026 Financial Results and Positive Obesity Pipeline Data
Viking Therapeutics (VKTX) reported a third-quarter net loss of $183.2 million, or $1.55 per share, driven by significant increases in research and development expenses as the company expands its Phase III clinical programs. Despite the losses, the company strengthened its balance sheet, ending the quarter with $960 million in cash and short-term investments following a $575 million gross proceeds raise through common stock and convertible notes. The company highlighted strong efficacy data for its VK2735 drug candidate, including subcutaneous weight reductions of up to 14.7% and oral formulations achieving up to 12.2% reduction in Phase II studies. Clinical momentum is high with the initiation of the Phase III SUNRISE program for oral dosing and rapid enrollment in the VANQUISH obesity registration studies. Management expects an average quarterly cash burn of approximately $100 million to support ongoing development and commercialization preparations.
Tickers: $VKTX
Topics: Clinical Trial Results Financial Performance R&D Expenses Weight Loss Drugs